AMG 595 First-in-Human in Recurrent Gliomas
NCT01475006
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
32
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Malignant Glioma
Anaplastic Astrocytomas
Glioblastoma Multiforme
Interventions
DRUG:
AMG 595
Sponsor
Amgen